Chemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer. - Wikidata - wikimedia - TriplyDB

Chemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer.

Chemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer.

http://www.wikidata.org/entity/Q37547962

about

Comment on "Chemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer".Chemotherapeutic-Induced Cardiovascular Dysfunction: Physiological Effects, Early Detection-The Role of Telomerase to Counteract Mitochondrial Defects and Oxidative Stress.

P2860

Q41870322-ACB679C7-27EF-42A8-A4E0-374982690E56 Q54959206-5245B0EC-003C-4828-80A1-BA63BFC89415

P2860

Chemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer.

http://www.wikidata.org/entity/Q37547962

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 December 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Chemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer.

@en

Chemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer.

@nl

type

label

Chemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer.

@en

Chemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer.

@nl

prefLabel

Chemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer.

@en

Chemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer.

@nl

P1433

Q37547962-684BE048-D764-46E3-A6BC-E758AE6B705C

P1476

Q37547962-844BD6D5-8CF9-4C31-864C-84A65568713F

P2093

Q37547962-042392AB-C35F-4E77-9145-D49EC822D219

Q37547962-045023E8-2F6A-4BD5-BBA9-6E51EDB5EE9E

Q37547962-30AC43B0-333E-40C4-8037-53E6111589DC

Q37547962-3C29E023-635A-4E3E-BBEC-7936291F1C14

Q37547962-3F0DEF5A-68C3-45DE-AEAA-97117AEB24D9

Q37547962-4EC02E21-BA67-4D7E-86EA-4CEF553997F2

Q37547962-5F8805C6-7912-4780-BDDD-F4201E3EFA96

Q37547962-6C0836EF-35F3-4468-886E-58822F617583

Q37547962-8FA1C1FA-E819-4509-B757-1AFB65C69420

Q37547962-D56896B0-14CE-42DE-9148-E39DBAADB348

P2860

Q37547962-1A0DD513-A989-4FF5-9C8F-DC1540192EA3

Q37547962-1CC872BE-E335-4BDD-BF29-2819608C3623

Q37547962-20436CCE-9A9B-489F-915A-993F18A89F19

Q37547962-2942BB6F-26D1-414C-9DBB-32AD8F547850

Q37547962-2F28217A-A007-470D-A70C-17ED6D55E28E

Q37547962-35271EC4-1C8A-4072-B451-586FE2FA4FFB

Q37547962-35B4FEE1-CB7E-4CDA-9F26-B9B22FEAFF69

Q37547962-36CD9B81-3BF2-46D1-B5A1-EB6A96CAEB87

Q37547962-4E95EE91-C26F-40AE-B0F8-5BA07327ED14

Q37547962-4E9FDCD4-3C4E-4823-8121-9E63649E2F05

P304

Q37547962-C82E75D6-F374-4050-9094-29ABE198B236

P31

Q37547962-C9B1AF82-381F-4F62-B0D1-6D257A1BBADB

P356

Q37547962-C01E18BD-52E4-4D70-966D-3EDA25E829DA

P433

Q37547962-8D217F85-F0E1-4A53-9FC0-1F271BC75E32

P478

Q37547962-99D321F3-940B-4C6C-9275-9898B099250B

P577

Q37547962-BE95A24E-790A-4AEE-A64B-32E2E4CC1076

P698

Q37547962-14EFEA8A-B979-4F1C-8F9F-F1725CCD64E9

P921

Q37547962-A4FAF618-F0BF-4D99-B845-07A3E1FD81E4

P932

Q37547962-D5D3AC2C-CDA0-4ECE-887C-00E447AF9819

P356

JBC.2016.19.4.402

P1433

Journal of breast cancer

P1476

Chemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer.

@en

P2093

Hyuk Jin Park

http://www.w3.org/2001/XMLSchema#string

Hyun Ju Yoon

http://www.w3.org/2001/XMLSchema#string

Hyung Wook Park

http://www.w3.org/2001/XMLSchema#string

Jae Yeong Cho

http://www.w3.org/2001/XMLSchema#string

Jeong Gwan Cho

http://www.w3.org/2001/XMLSchema#string

Jong Chun Park

http://www.w3.org/2001/XMLSchema#string

Jong Yoon Kim

http://www.w3.org/2001/XMLSchema#string

Ju Han Kim

http://www.w3.org/2001/XMLSchema#string

Kye Hun Kim

http://www.w3.org/2001/XMLSchema#string

Myung Ho Jeong

http://www.w3.org/2001/XMLSchema#string

P2860

Cardiac dysfunction in the trastuzumab clinical trials experience

Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.

Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.

Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment

Adjuvant trastuzumab in HER2-positive breast cancer.

Early cardiac function monitoring for detection of subclinical Doxorubicin cardiotoxicity in young adult patients with breast cancer.

Population-based breast cancer statistics in Korea during 1993-2002: incidence, mortality, and survival.

P304

402-409

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4048/JBC.2016.19.4.402

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28053628

http://www.w3.org/2001/XMLSchema#string

P921

P932

5204046

http://www.w3.org/2001/XMLSchema#string